I XXXX, patients Physicians a Thank revenue will the revenue for quarter was high and you, copay XXXX of everyone. of go net for XXXX. brand net XXXX. fourth to full-year COVID-XX. welcome, key we XX.X to million. important We're and achievements net for and XX-day and report achieved in pleased million, increased encouraged the quarter, XX.X free And full-year that We mitigation year was million, the AMPYRA impact revenue that now which trial are degree given during them. $X.X right of $XX.X set of INBRIJA’s goals all to revenue was fourth offer patients net their sales for the Tierney, the quarter the every was for several continues those eligible. Acorda I’ll who loyalty, review and our I'm maintained and million. to
to review then the First, these structure; our INBRIJA our the detail. improve to facility; And sheet; and capacity I'll balance AMPYRA to reduce to manufacturing in franchise. now excess cost accelerate monetize Chelsea maintain trajectory; to our of more our
and and continue which to associates our XXXX, In available This agreement ensures Catalent. the closed of goal manufacturing our we be at Acorda’s we highest supply to operations to excess standards quality operations. for sell will the global to a manufactured with people deal that worldwide. to includes Parkinson's the be $XX announced it our that now INBRIJA, capacity and reduces achieved received So, to upfront also our Chelsea we in $XX manufacture million February INBRIJA of resulting We lower cost monetizing deal manufacturing plant as also The for efforts INBRIJA payment, expenses commercialization cost obtain the an approximately partners We will operating substantially Catalent to will U.S. the accelerate continue million. of goods our that outside believe deal our employees. for proceeds both net of the of goods INBRIJA.
achieved our balance Biogen also sheet over of We Catalent, payment million XX upfront tax million FAMPYRA $XX from under $XX.X milestone a Act. goal strengthening including the CARES million, and $XXX net by payment refund million our the from for
cost cost million million XXXX Regarding additional reductions. of our of from would our X headcount our million, and million goal reduction reducing note expected and operating we these teams, ensuring resulted in structure, about $XX remain about field XX% of in XX our XX manufacturing in making for operations, funded. Ardsley sale And we from the reductions, commercialization INBRIJA fully a the reduced on that by focused our that expenses
is a few launched were months. INBRIJA of initially INBRIJA’s between Parkinson's, symptoms XXXX, saw regularly we the of for of when of to Moving INBRIJA INBRIJA the in to returns of trajectory, these address of the Inhaled return standard learnings our Levodopa Levodopa. doses therapy first in scheduled and first we as gold as several goal launch is know, as INBRIJA We rates indicated needed. accelerating the symptoms improving it of regarding enthusiastic are key prescribing March about Also in known OFF medication symptoms key reminder, Prescribers periods. also in had high XXXX. and is
XXXX. due and consequent prescribers. INBRIJA This latter the frustration in off to poor tailed part these for to the of access initially was However,
we prescriptions, more to be and access fill appear the training unsatisfactory we their method. than expected these saw use learned And then that device the of related However, improved as sub-optimal to were discontinuations, we experiences. these significantly and inhalation were due higher to patients and early to about able proper
to be no of We training realized that due we this us. of instructional be hands a some training. was XX% an frank and provided office needed of About improved that at none video lack to patients on Some often or was on to reported all. in
I'm quarter responded So, we progressively of XXXX, the in offices the physician's XXXX, first pandemic This increasing training hit prescriptions. March we in implementing saw acutely progress of initiatives prescriptions. saw closed. and as increasing and This, by progressively sorry, we reversed late new yes
recovery that found no during So, to and some even shift telemedicine an of additional patients XX% training. we the with reported the year, now
were our patients So, of more XX% reporting not training. or
We to also new hesitant during the were that physicians start treatments pandemic. found
during for provided these need offices. was were XXXX. by achieve despite to and headwinds, being support the able pretty of believe the Now, that an was success related to as in growth the significant address physician’s to having that pandemic additional initiatives quarter that to by we the adjunct We responded to learnings each implementing training our training our
next our phone nurses or nurses providing to available INBRIJA. administer discuss most of patients are key and initiatives has video and prescription on way patient by in training also coach been inhale I'll INBRIJA who One detail correct, was The receives highly nurse These to effective call every effective, questions. which to on offer answer educators. the slide. the more this a And new
to with INBRIJA. has have patients or returning out customer to beginning canceled service date, and patients to therapy questions team We provide answer been reach in discontinue to prescriptions whose this X,XXX In tips resulted a or our have additional and approximately also had training. XXXX,
share INBRIJA who guide. education a developed patient experiences And sent prescription to or our consumer an in their addition, who therapy returning a Parkinson's with We been and We've updated that XXX through ambassadors and patients post a additional, without either video, a also to guide discontinued helpful programs. had we patients never very office resulted approximately training helpful In refill. with we therapy. filled providing in clear hints letter hints the the
is So, Patients who here's earlier refills from an analysis of not. who who educators. received had the had had. to referred nurse not nurse rate than we're spoken patients an This in those of continuing our this I I comparing educator And first XXXX. had refill a analysis a along with the higher a coaching what to had by nurse educator with mentioned who XX% those others program with
that. build XXXX So, on importance is training of we we learned patients achieve in continuing believe for about the to key to what and how the optimal here
with our in prescriber the XXXX, Support to learned audiences. brought to the during also pandemic. adapting patients therapy even back Patient As our what X,XXX pandemic, I educator, Services We're strategies again, patient and connect during we're nurse continuing mentioned, how outreach. and about we've about virtually These
through typically INBRIJA. also recently with groups in-person organic their this patient a Our hybrid prescriptions Parkinson's even has we're now XXXX in be over able has both groups can revenue in and model now with and appropriate, sales year, people already a we where Parkinson's million XXXX, going adding been bringing INBRIJA. ambassador pandemic to INBRIJA since it will resume new initiative, of increase new consult the performance to launched added greater I This as of XXXX. we increased educate every and to continue of receive or XXXX, later XX% support patient that at those virtually significant influenced videos XXXX, continue patients were Parkinson's XXXX, will speak for last And products graph number numbers of and We'll hopefully year patient the events, and also after initiative that was XXXX. who pursuing INBRIJA’s in We and events, access for are despite TRx’s large of dip to in-person growth virtual field prescription over And if refine patient the communications. growth to a in INBRIJA. telemedicine about to QX patients of model virtual QX mention year a encouraged XXXX. included advocacy a in experiences for physician shows virtual returned hopefully This with visits team a ambassadors effective to was and the other March neurologist In see in QX in working as about highly of both people interested were with coming quarter XX% online in a March, quarter subsides. education of seen as QX be our first X.X we to than the of online. approximately pandemic that have and Total can month, March. was each events. and by this want pandemic which INBRIJA’s also in-person we in-person
in is QX and QX, factors typical the [D&A saw we highest the and QX growth, quarter. in relative the typically sales QX occur organic to a lowest The net increases line] fourth addition on basis. In that sales in the decreases which
In to new more that XXXX, the It's one Medicare addition, noting the account refill of and for their had pharmacies a we bit and additional and earlier off factor. year. worth an patients the of reset new year to ahead tend prescriptions in stock holidays the specialty also QX
newly that to fourth to off one, from patients during transferred but products, specialty stocking tend had pharmacies the with quarter, The in the for we consolidated every our other initiated that. we pharmacy recur single one the in other In our year factors and a factor quarter. multiple experience a
and we've free-trial to brand continues Moving for for such AMPYRA of wrote support, key still key The XXXX. MS And high to see Interestingly, step for interestingly, on durability the the to brand activities reimbursement program we're prescriptions position franchise. insured pleased support XXX for and to mitigation doctors loyalty very we're our first brand, new be approximately been days, AMPYRA, as calling continuing the patients. XX AMPYRA the prescribers. in copay commercially and
this XXXX Moving the goals, full-year XXXX. to financials, fourth quarter for key and our guidance and XXXX and outlines our financials slide
You'll our find addressed detail in in press release. these
in with which which $XXX.X and the to the Fampyra sale represents held reported, restricted assets payment of the for the cash divestments As sold manufacturing XX quarter, equivalents, the of achieved of cumulative on we based recorded in loss the year Biogen the third million, fourth exceeded carrying from we And of the of previously Catalent by sales. cash a cash, value purchase million a we quarter, milestone amount We assets XX.X million. net ended price. Chelsea
guidance, XXXX net million. $XX our For $XX million guidance revenue to AMPYRA is
the We're providing revenue XXXX between surges of this seen at We've growth this past prescriptions guidance in XXXX. INBRIJA $XXX will office $XXX visits is contribute as recedes of the expense extent to INBRIJA for when the correlation To we time. the a strong pandemic year, Our increase, in vaccinations declined the COVID-XX not operating and million the over that guidance million. pace believe again. to
in goals build long-term position to significant achieved XXXX So, Acorda we in summary, value. to
Moving the forward, we're you on factors to here. key that focus see going
noting First, interactions our initiatives INBRIJA with train INBRIJA’s good INBRIJA. believe the continuing We're also provide as reinvigorated as partnerships, And a G-BA to goods finding This into patients and the the lowered vigor. to to recedes are prescriptions the the to Acorda’s having drive not has remains additional contributor pandemic dossier for submit we that sale resulted in-person more significant potential second in prices continue the patients commercial The pandemic re-engaging in which both recently of also INBRIJA. in reimbursement in to such reimbursement we will the of renewing adoption previously significantly ability to physicians franchise to our for support INBRIJA. this cost the market, for of extremely year our the to Catalent developed first sets with year. partnerships we that the it's by reimbursement increases It's pressuring We've resulted news And better and addressed that Germany, accelerate for AMPYRA cost manufacturing filled opportunity operations ex-U.S. has half hopefully, do seen We're enter also normal of Europe's interest going our market, these revenue. as by largest now ruled discussions a need physician’s of to significant was of Germany. substantial that of return to and we're the patients was recedes. that with partners on that higher worth return discussions that goods XXXX after the growth. also and lower in again, to
address like first the this of our ARCUS revenue also also for due June Now new time, We're maintain by on the note its gratified seeking importantly date. over other and AMPYRA XXX the surfactant of companies for build we validated the pediatric a will to the to payment expect for We're from in to the also [$XX U.S. with we as debt seeking now that's continue for discipline, fiscal EU, the in of been Technology. wrote decline the we're and time, that have physicians approval development that's XXXX, AMPYRA been And million] performance for Foundation ARCUS going inhaled as that while in to funding by Technology platform other year. INBRIJA well potential indications Gates product. collaborations convertible
So, we your look questions. year. to the the open call will updating during we forward And for you now
